Todor Jeliaskov Appointed CEO of inHEART

inHEART, the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO. He will lead the French company in its mission to bridge the gap between cardiology and medical imaging with a digital twin of the patient’s heart. Todor Jeliaskov will work closely with co-founder and former CEO Jean-Marc Peyrat, who transitions to the role of CTO at inHEART.

“I am thrilled to welcome Todor as our new CEO,” said Jean-Marc Peyrat, co-founder of inHEART. “His proven leadership and experience perfectly complement our existing team to scale up the company and to support its ambition to be a major player in the double-digit growing market of cardiac electrophysiology.”

Todor Jeliaskov brings over 20 years of experience solving customers’ needs and generating returns for investors and shareholders at large, complex enterprises and startup organizations across continents and various industries. Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020. NuVera developed the next-generation of ultrasound imaging technology for cardiac interventions – 4D ICE. Todor Jeliaskov previously served as VP at GE Ultrasound, the worldwide market leader in diagnostic ultrasound. Todor Jeliaskov started his career at Siemens Medical Solutions. He holds a Ph.D. in Electrical Engineering and an MBA degree.

“I am honored to join the exceptionally talented inHEART team that developed a unique solution for the guidance of cardiac ablations. It is rare to see new technologies with such a substantial impact on patient care.” said Todor Jeliaskov. “I am excited to be part of this revolution and I look forward to driving its international deployment to make it accessible to most patients.”

“At Elaia, we congratulate Todor Jeliaskov on his selection as Chief Executive Officer, we’re excited by the tremendous progress inHEART has made since Elaia’s investment in 2020 under Jean-Marc Peyrat’s leadership as CEO and would like to thank him and welcome him as the new Chief Technology Officer of the company,” said Samantha Jérusalmy, Partner at Elaia. “We are confident that inHEART is poised for strong growth and Todor’s commercial leadership and management experience are unique assets in this new phase.” explains Sacha Loiseau, Venture Partner at Elaia.

SourceinHEART

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.